CN101829162A - Pharmaceutical composition for treating allergic rhinitis and preparation method thereof - Google Patents
Pharmaceutical composition for treating allergic rhinitis and preparation method thereof Download PDFInfo
- Publication number
- CN101829162A CN101829162A CN201010182489A CN201010182489A CN101829162A CN 101829162 A CN101829162 A CN 101829162A CN 201010182489 A CN201010182489 A CN 201010182489A CN 201010182489 A CN201010182489 A CN 201010182489A CN 101829162 A CN101829162 A CN 101829162A
- Authority
- CN
- China
- Prior art keywords
- time
- allergic rhinitis
- extract
- preparation
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010105 allergic rhinitis Diseases 0.000 title claims abstract description 42
- 206010039085 Rhinitis allergic Diseases 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 21
- 241000238675 Periplaneta americana Species 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- 239000000706 filtrate Substances 0.000 claims description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
- 238000001914 filtration Methods 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 22
- 239000002674 ointment Substances 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 19
- 238000003756 stirring Methods 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 13
- 239000008213 purified water Substances 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 12
- 238000004659 sterilization and disinfection Methods 0.000 claims description 12
- 235000014593 oils and fats Nutrition 0.000 claims description 7
- 238000004064 recycling Methods 0.000 claims description 7
- 239000000890 drug combination Substances 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- 230000035876 healing Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 241000218671 Ephedra Species 0.000 abstract 2
- 230000001737 promoting effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 4
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229960003291 chlorphenamine Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000015817 Infant Nutrition disease Diseases 0.000 description 2
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241000131808 Scolopendra Species 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- -1 violent Chemical compound 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- BRTLKRNVNFIOPJ-UHFFFAOYSA-N Betaine homarine Chemical compound C[N+]1=CC=CC=C1C([O-])=O BRTLKRNVNFIOPJ-UHFFFAOYSA-N 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- 241000238659 Blatta Species 0.000 description 1
- 241000238660 Blattidae Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000238661 Periplaneta Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102100029677 Trehalase Human genes 0.000 description 1
- 108010087472 Trehalase Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229940093497 ergothioneine Drugs 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 239000011499 joint compound Substances 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating allergic rhinitis, mainly comprising mixtures with effective components prepared from 1-2 parts by weight of periplaneta Americana extractive and 4-18 parts by weight of ephedra. The method for preparing the pharmaceutical composition for treating allergic rhinitis comprises the following steps of: extracting the periplaneta Americana extractive and the effective components of the ephedra, and mixing to prepare the medicine. The preparation method of the invention is simple, gives full play to the periplaneta Americana extractive, and effectively improves the healing effect of allergic rhinitis; and the pharmaceutical composition is a new medicament worth of promoting, is convenient to use and has little toxic and side-effect.
Description
Technical field
The present invention relates to medical technical field, be specifically related to pharmaceutical composition of a kind of treatment of allergic rhinitis and preparation method thereof.
Background technology
It is documented that periplaneta americana is the insecticide of volume maximum in the Blattidae, originates in South America, periplaneta americana is traditional Chinese crude drug, is used as medicine its property plug salty in the mouth with dry and bright adult, poisonous, acid is arranged, functions such as dissipating blood stasis, removing food stagnancy, detoxifcation, diuretic, detumescence are arranged; Curing mainly infantile malnutrition, tonsillitis, health enclosed mass, carbuncle skin ulcer swells and ache and Scolopendra, venom etc.
Along with science and technology constantly develops, after years of research and found that in recent years the periplaneta americana epidermis contains sclerotin and chitin, elements such as bromine, zinc, nickel, violent, potassium, calcium, titanium, chlorine, sulfur, silicon, aluminum, magnesium; Muscle hydrolysis 13 seed amino acids; Its alcohol extract has the obvious suppression effect to cancerous cell, and cardiovascular disease is had tangible curative effect.In addition, health storage vitamin B
1, B
2, nicotinic acid and ascorbic acid etc., lymph contain trehalose, trehalase, glycoprotein, inositol, protocatechuic acid Fructus Vitis viniferae glycoside etc.All contain ergothioneine, 1-methyl-2-pyridinium carboxylate, trigonelline, glycine, betanin, anus alkali, trimethylamine, adenine etc.Clinical main application has: treat infantile malnutrition, control the carbuncle pyogenic infections from tumour or sore, control the Scolopendra wound, control innominate toxic swelling, control the worm venom.But also have periplaneta americana and medical herbs compatibility auxiliary treatment colon cancer.American-cockroach-extract can be controlled hepatitis B, and extract A T-2 preparation can cure mainly primary hepatocarcinoma, cardiovascular disease etc.
Notification number is CN 100525781C, name is called " American-cockroach-extract; contain pharmaceutical composition of this extract and preparation method thereof " and publication number is CN1943600A, it is two with the American-cockroach-extract relevant patent documentations of applicant in application in 2006 that name is called " pharmaceutical composition and the new purposes thereof that contain periplaneta americana and ethanol extraction thereof ", it discloses the preparation method and the part medical usage of American-cockroach-extract, in recent years, along with the further research to American-cockroach-extract, American-cockroach-extract has obtained further development in purposes pharmaceutically.
Allergic rhinitis is allergic rhinitis (allergic rhintis) again, is the allergic disease of nasal membrane, and can causes multiple complications.Sickness rate has rising to warm up in recent years.Allergic rhinitis is morbidity easily in the winter time generally, and the branch of long-term property, seasonality is arranged.Seasonal allergic rhinitis then is the outbreak in season, how in spring, morbidity in autumn.Classical symptom is that nasal obstruction, rhinocnesmus, headache, paroxysmal sneeze are shown effect continuously, a large amount of water sample nasal mucus and olfactory disorder etc.Badly influence patient's the quality of life so that the health status of whole machine body, also have influence on patient's doings and physical work.For example the allergic rhinitis outbreak time is difficult to the work of concentrating one's energy, if attend a meeting or in other public arenas outbreaks, also can bring embarrassed sensation to the people.The expert points out that allergic rhinitis should be treated as early as possible, otherwise can cause allergic asthma.
The allergic rhinitis common method of treatment has: 1, avoid therapy; 2, pharmacotherapy; 3, intranasal spray; 4, nasal injection method; 5, electricity burns or cryotherapy; 6, laser therapy; 7, hyposensitization; 8, hands art; 9, traditional Chinese medical science intranasal point medicine method.
At present, doctor trained in Western medicine is many to the many employings of the treatment of allergic rhinitis with antihistamine drug for oral administration, the interim inhibition of corticosteroids medicine, as oral western medicine, oral hormone, externally used solution lotion, Emulsion, mud cream, oil preparation, ointment, Emulsion, liniment, tincture and plaster etc.The corticosteroids medicine is used in long-time or heavy dose of external, can addiction cause drug dependence, and modal is that sb.'s illness took a favorable turn after the medication, in case after the drug withdrawal, the agents area primary affection increases the weight of.After again with hormone, above-mentioned sb.'s illness took a favorable turn or disappearance; As drug withdrawal again, knock-on property is sent out again, and than more serious in the past.
In sum, existing medicine still has unsatisfactory part for treatment of allergic rhinitis.For this reason, the invention provides a kind of new pharmaceutical composition that is used for the treatment of allergic rhinitis.
Summary of the invention
The objective of the invention is to: overcome above-mentioned deficiency of the prior art, a kind of pharmaceutical composition and preparation method thereof of treatment of allergic rhinitis of effective raising cure rate is provided.
Purpose of the present invention is achieved through the following technical solutions: a kind of pharmaceutical composition of treatment of allergic rhinitis is provided, it is characterized in that: the main component of described pharmaceutical composition and mass parts thereof are such as shown in down: 1～2 part of American-cockroach-extract; 4～18 parts in Herba Ephedrae.
The proportioning of one of preferred version of the pharmaceutical composition of above-mentioned treatment of allergic rhinitis is: 1 part of American-cockroach-extract; 8 parts in Herba Ephedrae.
Two proportioning of the preferred version of the pharmaceutical composition of above-mentioned treatment of allergic rhinitis is: 2 parts of American-cockroach-extracts; 15 parts in Herba Ephedrae.
The preparation of drug combination method of above-mentioned treatment of allergic rhinitis may further comprise the steps:
1., the preparation of American-cockroach-extract:
A, coarse crushing: exsiccant periplaneta americana is pulverized, make the periplaneta americana coarse powder;
B, immersion: will add the water of 3～5 times of amounts in the coarse powder among the step a, soak and made the coarse powder mixed liquor in 0.5～2 hour, soaking temperature is 70 ℃～78 ℃, and the coarse powder mixed liquor adopts the method that decocts to carry out three times and extracts, and makes extracting solution;
C, three extractions: the coarse powder mixed liquor is carried out the first time extract, extraction time is 7～9 hours; Carry out the second time then behind the water that adds 2～4 times of amounts of surplus liquid in the surplus liquid after extracting for the first time and extract, extraction time is 5～7 hours; Extract for the third time behind the water that adds 2～4 times of amounts of surplus liquid in the surplus liquid after extracting for the second time at last, extraction time is 3～5 hours;
D, filtration for the first time: the extracting solution that three times are extracted among the step c is merged mixing, filter then and make one-level filtrate;
E, concentrated for the first time: relative density was 1.05～1.25 one-level concentrated solution when the one-level filtrate in the steps d was concentrated into 70 ℃～90 ℃;
F, alcoholization are handled: add the ethanol that concentration is 93%w/w～97%w/w in the one-level concentrated solution that makes in step e gradually, and fully stir, making it contain the alcohol amount reaches till 45%～55%, under 70 ℃～90 ℃ temperature conditions, be incubated 20～40 minutes, left standstill then 10～14 hours, and made solution of alcoholized;
G, filtration for the second time: the solution of alcoholized among the step f is discarded the upper strata oils and fats, and lower floor's medicinal liquid filters and makes secondary filtrate;
H, the second time concentrate: after the secondary filtrate in the step g was carried out the ethanol recycling, relative density was 1.20～1.25 secondary concentrated solution when being concentrated into 70 ℃～90 ℃;
I, unguentum preparation: the unguentum that the secondary concentrated solution among the step h is concentrated into moisture≤25%～35% under condition of normal pressure;
J, extract preparation: according to unguentum: the ratio of purified water: glycerol=1000g: 800ml～1200ml: 4ml～6ml adds purified water and glycerol in unguentum, stir, through plate-and-frame filtration, after filtrate is boiled 30 minutes, be chilled to room temperature, promptly get American-cockroach-extract, standby;
2., Herba Ephedrae is decocted with water twice, 2～4 hours for the first time, 1～3 hour for the second time, decocting liquid filtered filtrate merging, and sheet frame filters, and is concentrated into an amount of, standby;
3., with step 1. with step in 2. prepared two kinds of extracts mix and stir, through plate-and-frame filtration, after filtrate is boiled 2～40 minutes, again through the autoclave sterilization postcooling to room temperature, promptly get patent medicine.
Amount of water is 4 times of amounts in above-mentioned steps b, and soak time is 1 hour, and soaking temperature is 74 ℃.
At the autoclave sterilization of above-mentioned steps described in 3. is to carry out sterilization under 115 ℃～127 ℃ of temperature, pressure are the condition of 0.05Mpa～0.15Mpa, and sterilization time is 25～35 minutes.
In sum, the preparation of drug combination method that is used for the treatment of allergic rhinitis provided by the present invention is simple, and given full play to the effect of American-cockroach-extract, effectively improved curative effect to allergic rhinitis, and easy to use, toxic and side effects is little, is a kind of new medicine that is worthy to be popularized.
The specific embodiment
Below in conjunction with embodiment the specific embodiment of the present invention is described in further detail:
The main component of the pharmaceutical composition of treatment of allergic rhinitis provided by the present invention and mass parts ratio thereof are: 1～2 part of American-cockroach-extract; 4～18 parts in Herba Ephedrae.
The proportioning of one of preferred version of the pharmaceutical composition of above-mentioned treatment of allergic rhinitis is: 1 part of American-cockroach-extract; 8 parts in Herba Ephedrae.
Two proportioning of the preferred version of the pharmaceutical composition of above-mentioned treatment of allergic rhinitis is: 2 parts of American-cockroach-extracts; 15 parts in Herba Ephedrae.
The preparation of drug combination method of above-mentioned treatment of allergic rhinitis may further comprise the steps:
1., the preparation of American-cockroach-extract:
A, coarse crushing: exsiccant periplaneta americana is pulverized, make the periplaneta americana coarse powder;
B, immersion: will add the water of 3～5 times of amounts in the coarse powder among the step a, soak and made the coarse powder mixed liquor in 0.5～2 hour, soaking temperature is 70 ℃～78 ℃, and the coarse powder mixed liquor adopts the method that decocts to carry out three times and extracts, and makes extracting solution;
C, three extractions: the coarse powder mixed liquor is carried out the first time extract, extraction time is 7～9 hours; Carry out the second time then behind the water that adds 2～4 times of amounts of surplus liquid in the surplus liquid after extracting for the first time and extract, extraction time is 5～7 hours; Extract for the third time behind the water that adds 2～4 times of amounts of surplus liquid in the surplus liquid after extracting for the second time at last, extraction time is 3～5 hours;
D, filtration for the first time: the extracting solution that three times are extracted among the step c is merged mixing, filter then and make one-level filtrate;
E, concentrated for the first time: relative density was 1.05～1.25 one-level concentrated solution when the one-level filtrate in the steps d was concentrated into 70 ℃～90 ℃;
F, alcoholization are handled: add the ethanol that concentration is 93%w/w～97%w/w in the one-level concentrated solution that makes in step e gradually, and fully stir, making it contain the alcohol amount reaches till 45%～55%, under 70 ℃～90 ℃ temperature conditions, be incubated 20～40 minutes, left standstill then 10～14 hours, and made solution of alcoholized;
G, filtration for the second time: the solution of alcoholized among the step f is discarded the upper strata oils and fats, and lower floor's medicinal liquid filters and makes secondary filtrate;
H, the second time concentrate: after the secondary filtrate in the step g was carried out the ethanol recycling, relative density was 1.20～1.25 secondary concentrated solution when being concentrated into 70 ℃～90 ℃;
I, unguentum preparation: the unguentum that the secondary concentrated solution among the step h is concentrated into moisture≤25%～35% under condition of normal pressure;
J, extract preparation: according to unguentum: the ratio of purified water: glycerol=1000g: 800ml～1200ml: 4ml～6ml adds purified water and glycerol in unguentum, stir, through plate-and-frame filtration, after filtrate is boiled 30 minutes, be chilled to room temperature, promptly get American-cockroach-extract, standby;
2., Herba Ephedrae is decocted with water twice, 2～4 hours for the first time, 1～3 hour for the second time, decocting liquid filtered filtrate merging, and sheet frame filters, and is concentrated into an amount of, standby;
3., with step 1. with step in 2. prepared two kinds of extracts mix and stir, through plate-and-frame filtration, after filtrate is boiled 2～40 minutes, again through the autoclave sterilization postcooling to room temperature, promptly get patent medicine.
Amount of water is 4 times of amounts in above-mentioned steps b, and soak time is 1 hour, and soaking temperature is 74 ℃.
At the autoclave sterilization of above-mentioned steps described in 3. is to carry out sterilization under 115 ℃～127 ℃ of temperature, pressure are the condition of 0.05Mpa～0.15Mpa, and sterilization time is 25～35 minutes.
Embodiment 1:
The prescription that is adopted is: 1 part of American-cockroach-extract; 8 parts in Herba Ephedrae.
Preparation method is: with exsiccant periplaneta americana coarse crushing, every 100Kg coarse powder adds 300Kg water, soaks after 0.5 hour, and temperature is extracted three times about 70 ℃, 7 hours for the first time; For the second time add water 200Kg, extracted 5 hours; Add water 200Kg for the third time, extracted 3 hours.Merge three times extracting solution, filter, when filtrate was concentrated into relative density and is 1.05 (70 ℃), adding concentration was the ethanol of 93%w/w, make that to become to contain alcohol amount be 45%, 70 ℃ of insulated and stirred 20 minutes left standstill 10 hours, discarded the upper strata oils and fats, lower floor's medical filtration, filtrate recycling ethanol, being evaporated to relative density is 1.20 (70 ℃), normal pressure is concentrated into the cream of moisture≤25%; Herba Ephedrae is decocted with water twice, and 2 hours for the first time, 1 hour for the second time, decocting liquid filtered filtrate merging, and sheet frame filters, and is concentrated into an amount of, standby; To stir after above-mentioned two kinds of extracts mixing, through plate-and-frame filtration, after filtrate was boiled 20 minutes, again through 115 ℃, pressure was 0.05Mpa, sterilized 25 minutes, was chilled to room temperature, promptly.
Embodiment 2:
The prescription that is adopted is: 2 parts of American-cockroach-extracts; 15 parts in Herba Ephedrae.
Preparation method is: with exsiccant periplaneta americana coarse crushing, every 100Kg coarse powder adds 500Kg water, soaks after 2 hours, and temperature is extracted three times about 78 ℃, 9 hours for the first time; For the second time add water 400Kg, extracted 7 hours; Add water 400Kg for the third time, extracted 5 hours.Merge three times extracting solution, filter, when filtrate was concentrated into relative density and is 1.25 (90 ℃), adding concentration was the ethanol of 97%w/w, make that to become to contain alcohol amount be 55%, 90 ℃ of insulated and stirred 40 minutes left standstill 14 hours, discarded the upper strata oils and fats, lower floor's medical filtration, filtrate recycling ethanol, being evaporated to relative density is 1.25 (90 ℃), normal pressure is concentrated into the unguentum of moisture≤35%; According to unguentum: the ratio of purified water: glycerol=1000g: 1200ml: 6ml adds purified water and glycerol in unguentum, stir, and through plate-and-frame filtration, filtrate is chilled to room temperature after boiling 30 minutes, promptly gets American-cockroach-extract, and is standby; Herba Ephedrae is decocted with water twice, and 4 hours for the first time, 3 hours for the second time, decocting liquid filtered filtrate merging, and sheet frame filters, and is concentrated into an amount of, standby; To stir after above-mentioned two kinds of extracts mixing, through plate-and-frame filtration, after filtrate was boiled 40 minutes, again through 127 ℃, pressure was 0.15Mpa, sterilized 35 minutes, was chilled to room temperature, promptly.
Embodiment 3:
The prescription that is adopted is: 1 part of American-cockroach-extract; 18 parts in Herba Ephedrae.
Preparation method is: with exsiccant periplaneta americana coarse crushing, every 100Kg coarse powder adds 400Kg water, soaks after 1 hour, and temperature is extracted three times about 74 ℃, 8 hours for the first time; For the second time add water 300Kg, extracted 6 hours; Add water 300Kg for the third time, extracted 4 hours.Merge three times extracting solution, filter, when filtrate was concentrated into relative density and is 1.15 (80 ℃), adding concentration was the ethanol of 95%w/w, make that to become to contain alcohol amount be 50%, 80 ℃ of insulated and stirred 30 minutes left standstill 12 hours, discarded the upper strata oils and fats, lower floor's medical filtration, filtrate recycling ethanol, being evaporated to relative density is 1.25 (80 ℃), normal pressure is concentrated into the unguentum of moisture≤30%; According to unguentum: the ratio of purified water: glycerol=1000g: 1000ml: 5ml adds purified water and glycerol in unguentum, stir, and through plate-and-frame filtration, filtrate is chilled to room temperature after boiling 30 minutes, promptly gets American-cockroach-extract, and is standby; Herba Ephedrae is decocted with water twice, and 3 hours for the first time, 2 hours for the second time, decocting liquid filtered filtrate merging, and sheet frame filters, and is concentrated into an amount of, standby; To stir after above-mentioned two kinds of extracts mixing, through plate-and-frame filtration, after filtrate was boiled 35 minutes, again through 121 ℃, pressure was 0.1Mpa, sterilized 30 minutes, was chilled to room temperature, promptly.
Embodiment 4:
The prescription that is adopted is: 2 parts of American-cockroach-extracts; 13 parts in Herba Ephedrae.
Preparation method is: with exsiccant periplaneta americana coarse crushing, every 100Kg coarse powder adds 380Kg water, soaks after 0.8 hour, and temperature is extracted three times about 74 ℃, 7.5 hours for the first time; For the second time add water 280Kg, extracted 5 hours; Add water 280Kg for the third time, extracted 3 hours.Merge three times extracting solution, filter, when filtrate was concentrated into relative density and is 1.2 (80 ℃), adding concentration was the ethanol of 95%w/w, make that to become to contain alcohol amount be 50%, 80 ℃ of insulated and stirred 30 minutes left standstill 11 hours, discarded the upper strata oils and fats, lower floor's medical filtration, filtrate recycling ethanol, being evaporated to relative density is 1.20 (80 ℃), normal pressure is concentrated into the unguentum of moisture≤30%; According to unguentum: the ratio of purified water: glycerol=1000g: 1100ml: 6ml adds purified water and glycerol in unguentum, stir, and through plate-and-frame filtration, filtrate is chilled to room temperature after boiling 30 minutes, promptly gets American-cockroach-extract, and is standby; Herba Ephedrae is decocted with water twice, and 2 hours for the first time, 2 hours for the second time, decocting liquid filtered filtrate merging, and sheet frame filters, and is concentrated into an amount of, standby; To stir after above-mentioned two kinds of extracts mixing, through plate-and-frame filtration, after filtrate was boiled 30 minutes, again through 121 ℃, pressure was 0.1Mpa, sterilized 30 minutes, was chilled to room temperature, promptly.
The pharmaceutical composition of treatment of allergic rhinitis provided by the present invention can be made various ways such as tablet, suppository, capsule, is beneficial to satisfy different patients' medication custom.
The clinical testing data of allergic rhinitis cure rate:
One, patient's classified data:
Allergic Rhinitis 99 examples meet diagnostic criteria.Be divided into treatment group and matched group at random, 52 examples are organized in treatment, male's 28 examples, women's 24 examples, 16～40 years old age; Matched group 47 examples, male's 24 examples, women's 23 examples, 16～40 years old age.Two groups of patient ages, sex and courses of disease are learned processing by statistics, and difference does not have the significance meaning, has comparability.
Two, Therapeutic Method:
The treatment group: get tablet according to drug prepared of the present invention, oral, once two, twice on the one.
Matched group: chlorphenamine, oral, once two, twice on the one.
Three, curative effect comparative result:
Table 1 is depicted as two groups of curative effects relatively, and wherein 52 examples are organized in treatment, cure 48 examples, and cure rate is 92.31%, and total effective rate is 100%; Matched group 47 examples are cured 35 examples, and cure rate is 74.47%, and total effective rate is 95.75%.Table 2 is depicted as two groups of 7 days curative effects relatively, treats in 7 days, and treatment group cure rate is 78.85%, and the matched group cure rate is 51.06%.This shows that treatment group curative effect obviously is better than matched group.(n number of delegates in table 1 and the table 2)
Table 1
Table 2
| Group | ??n | 7 days healing patient numbers | 7 days cure rates (%) |
| The treatment group | ??52 | ??41 | ?78.85 |
| Matched group | ??47 | ??24 | ?51.06 |
Four, conclusion (of pressure testing):
The generation of allergic rhinitis is relevant with multiple factor, and common have infection, immunity or the like.Chlorphenamine is a kind of medicine that is usually used in the allergic rhinitis treatment, and certain curative effect is arranged.Periplaneta americana is a kind of insecticide, be commonly called as Blatta seu periplaneta, body contains the various active composition, its extract main component is polyalcohols and peptide class active substance, confirms effect with enhance immunity through pharmacological research, but does not have antibacterial action, the medicine that American-cockroach-extract and Herba Ephedrae are made not only can infection, simultaneously can promote the quick rehabilitation of allergic rhinitis, improve the allergic rhinitis cure rate, shorten the allergic rhinitis healing time.Comparing data shows that the curative effect that this medicine is used for the treatment of allergic rhinitis obviously is better than medicine chlorphenamine commonly used.
Though in conjunction with specific embodiments the specific embodiment of the present invention has been done to describe in detail, should not be construed as is limitation of the invention.In the protection domain that claims limited, various modifications that those skilled in the art can make without creative work or distortion still belong to the protection domain of this patent.
Claims (6)
1. the pharmaceutical composition of a treatment of allergic rhinitis is characterized in that: the main component of described pharmaceutical composition and mass parts thereof are such as shown in down:
1～2 part of American-cockroach-extract;
4～18 parts in Herba Ephedrae.
2. the pharmaceutical composition of treatment of allergic rhinitis according to claim 1 is characterized in that: the main component of described pharmaceutical composition and mass parts thereof are such as shown in down:
1 part of American-cockroach-extract;
8 parts in Herba Ephedrae.
3. the pharmaceutical composition of treatment of allergic rhinitis according to claim 1 is characterized in that: the main component of described pharmaceutical composition and mass parts thereof are such as shown in down:
2 parts of American-cockroach-extracts;
15 parts in Herba Ephedrae.
4. the preparation of drug combination method of a claim 1,2 or 3 described treatment of allergic rhinitis, it is characterized in that: described preparation method may further comprise the steps:
1., the preparation of American-cockroach-extract:
A, coarse crushing: exsiccant periplaneta americana is pulverized, make the periplaneta americana coarse powder;
B, immersion: will add the water of 3～5 times of amounts in the coarse powder among the step a, soak and made the coarse powder mixed liquor in 0.5～2 hour, soaking temperature is 70 ℃～78 ℃, and the coarse powder mixed liquor adopts the method that decocts to carry out three times and extracts, and makes extracting solution;
C, three extractions: the coarse powder mixed liquor is carried out the first time extract, extraction time is 7～9 hours; Carry out the second time then behind the water that adds 2～4 times of amounts of surplus liquid in the surplus liquid after extracting for the first time and extract, extraction time is 5～7 hours; Extract for the third time behind the water that adds 2～4 times of amounts of surplus liquid in the surplus liquid after extracting for the second time at last, extraction time is 3～5 hours;
D, filtration for the first time: the extracting solution that three times are extracted among the step c is merged mixing, filter then and make one-level filtrate;
E, concentrated for the first time: relative density was 1.05～1.25 one-level concentrated solution when the one-level filtrate in the steps d was concentrated into 70 ℃～90 ℃;
F, alcoholization are handled: add the ethanol that concentration is 93%w/w～97%w/w in the one-level concentrated solution that makes in step e gradually, and fully stir, making it contain the alcohol amount reaches till 45%～55%, under 70 ℃～90 ℃ temperature conditions, be incubated 20～40 minutes, left standstill then 10～14 hours, and made solution of alcoholized;
G, filtration for the second time: the solution of alcoholized among the step f is discarded the upper strata oils and fats, and lower floor's medicinal liquid filters and makes secondary filtrate;
H, the second time concentrate: after the secondary filtrate in the step g was carried out the ethanol recycling, relative density was 1.20～1.25 secondary concentrated solution when being concentrated into 70 ℃～90 ℃;
I, unguentum preparation: the unguentum that the secondary concentrated solution among the step h is concentrated into moisture≤25%～35% under condition of normal pressure;
J, extract preparation: according to unguentum: the ratio of purified water: glycerol=1000g: 800ml～1200ml: 4ml～6ml adds purified water and glycerol in unguentum, stir, through plate-and-frame filtration, after filtrate is boiled 30 minutes, be chilled to room temperature, promptly get American-cockroach-extract, standby;
2., Herba Ephedrae is decocted with water twice, 2～4 hours for the first time, 1～3 hour for the second time, decocting liquid filtered filtrate merging, and sheet frame filters, and is concentrated into an amount of, standby;
3., with step 1. with step in 2. prepared two kinds of extracts mix and stir, through plate-and-frame filtration, after filtrate is boiled 20～40 minutes, again through the autoclave sterilization postcooling to room temperature, promptly get patent medicine.
5. the preparation of drug combination method of treatment of allergic rhinitis according to claim 4, it is characterized in that: amount of water is 4 times of amounts among the described step b, and soak time is 1 hour, and soaking temperature is 74 ℃.
6. the preparation of drug combination method of treatment of allergic rhinitis according to claim 4, it is characterized in that: described step 3. in autoclave sterilization be under 115 ℃～127 ℃ of temperature, pressure are the condition of 0.05Mpa～0.15Mpa, to carry out sterilization, sterilization time is 25～35 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101824890A CN101829162B (en) | 2010-05-25 | 2010-05-25 | Pharmaceutical composition for treating allergic rhinitis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101824890A CN101829162B (en) | 2010-05-25 | 2010-05-25 | Pharmaceutical composition for treating allergic rhinitis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101829162A true CN101829162A (en) | 2010-09-15 |
| CN101829162B CN101829162B (en) | 2012-06-27 |
Family
ID=42713483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101824890A Active CN101829162B (en) | 2010-05-25 | 2010-05-25 | Pharmaceutical composition for treating allergic rhinitis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101829162B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104721234A (en) * | 2013-12-20 | 2015-06-24 | 舒梅 | Periplaneta Americana extract product ion-activated in-situ gel and preparation method thereof |
| CN107638429A (en) * | 2017-04-08 | 2018-01-30 | 昆明赛诺制药股份有限公司 | A kind of medicine for treating rhinitis and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939345A (en) * | 2006-09-30 | 2007-04-04 | 耿福能 | American falx extract, medicinal composition containing it and its making method |
-
2010
- 2010-05-25 CN CN2010101824890A patent/CN101829162B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939345A (en) * | 2006-09-30 | 2007-04-04 | 耿福能 | American falx extract, medicinal composition containing it and its making method |
Non-Patent Citations (1)
| Title |
|---|
| 《中外医疗》 20091231 祝庆海 麻黄附子细辛汤配合洗鼻法治疗过敏性鼻炎的体会 109-110 1-6 , 第24期 2 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104721234A (en) * | 2013-12-20 | 2015-06-24 | 舒梅 | Periplaneta Americana extract product ion-activated in-situ gel and preparation method thereof |
| CN107638429A (en) * | 2017-04-08 | 2018-01-30 | 昆明赛诺制药股份有限公司 | A kind of medicine for treating rhinitis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101829162B (en) | 2012-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101850047A (en) | Chinese medicinal composition for treating eczema and preparation thereof | |
| CN101829178B (en) | Medicine composition for treating diaper rash and preparation method thereof | |
| CN101837019B (en) | American cockroach medicinal composition for curing oral ulcers and preparation method thereof | |
| CN101837045A (en) | American cockroach medicinal composition for curing oral ulcers and preparation method thereof | |
| CN101837095A (en) | American cockroach medicinal composition for curing gastritis and peptic ulcers and preparation method thereof | |
| CN101829162B (en) | Pharmaceutical composition for treating allergic rhinitis and preparation method thereof | |
| CN102274317A (en) | Chinese medicinal composition for treating cancers and preparation method thereof | |
| CN101822696B (en) | Medicine composite for treating burn and scald and preparation method thereof | |
| CN101829193B (en) | Medicine composite for treating cervical erosion and preparation method thereof | |
| CN103751309A (en) | Traditional Chinese medicine external preparation for treating intercostal neuralgia and preparation method thereof | |
| CN103520289B (en) | A kind of Chinese medicine composition for the treatment of constipation and its preparation method and application | |
| CN104096018A (en) | Traditional Chinese medicine composition for treating facial neural paralysis | |
| CN101829167B (en) | Medicine composite for treating cervical erosion and preparation method thereof | |
| CN101829253B (en) | Medicine composite for treating cervical erosion and preparation method thereof | |
| CN101837023A (en) | American cockroach medicinal composition for curing gastritis and peptic ulcers and preparation method thereof | |
| CN102697964B (en) | Medicine for treating male sexual dysfunction | |
| CN101829220B (en) | Periplaneta Americana pharmaceutical composition for treating ulcerative colitis and preparation method thereof | |
| CN101829177B (en) | Medicine composition for postoperative wound restoration and preparation method thereof | |
| CN101829168B (en) | Pharmaceutical composition for treating condyloma acuminatum and herpes, as well as preparation method thereof | |
| CN105106590A (en) | Medicine for treating allergic rhinitis | |
| CN1329053C (en) | Externally applied agent for treating wean hives | |
| CN103933169A (en) | Traditional Chinese medicine composition for fumigating and treating deaf and tinnitus and preparation method and application thereof | |
| CN105031165A (en) | Traditional Chinese medicine for treating nerve headache and preparation method thereof | |
| CN105641576A (en) | External ointment for treating various skin warts | |
| CN103977296A (en) | Traditional Chinese medicine oral solution for treating urethritis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200824 Address after: 615000 Liangshan Yi Autonomous Prefecture, Xichang province Sichuan Airport Road Patentee after: SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL Co.,Ltd. Address before: 15, building 88, building B, four Wei building, No. 610031 Camp Road, Sichuan, Chengdu Patentee before: Geng Funeng |
|
| TR01 | Transfer of patent right |